Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies

European Journal of Haematology

Volumn 78, Issue 4, 2007, Pages 275-282

  Maertens, Johan ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b Acute Leukemia and Transplantation Unit ^*  (Belgium)

Author keywords

Antifungal agents; Mycoses; Posaconazole; Review

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; PLACEBO; POSACONAZOLE; PYRROLE DERIVATIVE;

ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; CANCER PATIENT; CANCER RISK; CANDIDA ALBICANS; CLINICAL TRIAL; DRUG EFFICACY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; INCIDENCE; MEDLINE; MORBIDITY; MORTALITY; MUCORMYCOSIS; MYCOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

ANTIFUNGAL AGENTS; COMORBIDITY; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES; RISK FACTORS; TREATMENT OUTCOME;

EID: 33847626540     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00805.x     Document Type: Review

References (56)

1. Bow EJ. Infection risk and cancer chemotherapy: the impact of the chemotherapeutic regimen in patients with lymphoma and solid tissue malignancies. J Antimicrob Chemother 1998;41:1-5.
2. O'Brien SN, Blijlevens NMA, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program 2003;438-72.
3. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995;21:361-9.
4. Prentice HG, Kibbler CC, Prentice AG. Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 2000;110:273-84.
5. Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-52.
6. Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, Corey L, Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000;96:2055-2061.
7. Cornely OA, Bohme A, Buchheidt D, et al. Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003;82:S186-S200.
8. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005;56:i23-i32.
9. Trifilio S, Verma A, Mehta J. Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice. Bone Marrow Transplant 2004;33:735-9.
10. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002;100:4358-66.
11. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002;34:909-17.
12. Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005;17:89-92.
13. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2002;15:569-74.
14. Marr KA. Invasive Candida infections: the changing epidemiology. Oncology (Huntingt) 2004;18:9-14.
15. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:627-30.
16. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66.
17. Hanna H, Kontoyiannis D, Buddineni J, Boktour M, Antoniadou A, Hachem R, Raad I. The changing epidemiology of candidemia in hematologic malignancy (HM): Candida glabrata and Candida krusei are the leading causes of fungemia [abstract M989]. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, December 16-19, 2005, pp 428.
18. Munoz P, Sanchez-Somolinos M, Alcala L, Rodriguez-Creixems M, Pelaez T, Bouza E. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother 2005;55:188-93.
19. Lionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazolepre-exposed cancer patients with positive cultures for aspergilli. Diagn Microbiol Infect Dis 2005;52:15-20.
20. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91:1068-75.
21. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60.
22. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006;106:2258-66.
23. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
24. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF, Urbano-Ispizua A, Brunet S, De la Camara R, for the alloPBSCT and Infectious/Non-infectious Complications Subcommittees of the Grupo Espanol de Transplante Hematopoyetico. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002;116:475-82.
25. Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974-90.
26. Anaissie EJ, Rex JH, Uzun O, Vartivarian S. Predictors of adverse outcome in cancer patients with candidemia. Am J Med 1998;104:238-45.
27. Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002;16:875-94.
28. McLintock LA, Jordanides NE, Allan EK, Copland M, Stewart K, Parker A, Devaney M, Holyoake TL, Jones BL. The use of a risk group stratification in the management of invasive fungal infection: a prospective validation. Br J Haematol 2004;124:403-4.
29. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099- 100.
30. Nath DS, Kandaswamy R, Gruessner R, Sutherland DE, Dunn DL, Humar A. Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc 2005;37:934-6.
31. Bow EJ, Laverdiere M, Lussier N, Rotstein C, Cheang MS, Ioannou S. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 2002;94:3230-46.
32. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials. Cancer 2000;89:1611-25.
33. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003;21:4615-26.
34. Morgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW, on behalf of the UK Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999;105:901-11.
35. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006;57:317-25.
36. Oren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006;38:127-34.
37. Annaloro C, Oriani A, Tagliaferri E, Bertolli V, Della Volpe A, Soligo D, Ibatici A, Pozzoli E, Lambertenghi Deliliers G. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995;80:512-17.
38. Huijgens PC, Simoons-Smit AM, van Loenen AC, Prooy E, Van TH, Ossenkoppele GJ, Jonkhoff AR. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999;52:376-80.
39. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004;103:1527-33.
40. Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003;138:705-13.
41. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 2005;131:22-8.
42. van Burik JA, Ratanatharathorn V, Stepan DE, et al., for the National institutes of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39:1407-16.
43. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 2006;50:143-7.
44. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction: chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003;97:450-6.
45. Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 2000;25:853-9.
46. Maertens J, Frére P, Lass-Flörl C, Heinz W, Cornely O. European guidelines for primary antifungal prophylaxis in leukemia patients. Presented at the 14th International Symposium of Infections in the Immunocompromised Host. July 2-5, 2006. Switzerland: Crans-Montana, 2006.
47. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood 2003;101:3365-72.
48. Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract 2004;58:612-24.
49. Keating GM. Posaconazole. Drugs 2005;11:1553-67.
50. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, Loebenberg D, Black TA, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15.
51. Cornely O, Maertens J, Winston D, et al. Posaconazole vs standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: results of a randomized, multicenter trial [abstract]. Blood 2005;106:524A.
52. Cornely OA, Maertens J, Durrant S, et al. Mortality in patients at high risk for invasive fungal infection: effect of posaconazole prophylaxis. Poster presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases. April 1-4, 2006. France: Nice, 2006.
53. Maertens J, Cornely OA, Winston DJ, et al. Prophylaxis of invasive fungal infection with posaconazole or standard azoles (fluconazole/ itraconazole) in patients with acute myelogenous leukemia or myelodysplastic syndrome and chemotherapy-induced neutropenia: results of a randomized multicenter trial [abstract]. Bone Marrow Transplant 2006;37:S29.
54. Maertens J, Ullmann AJ, Durrant S, et al. Posaconazole as prophylaxis for invasive fungal infections in high-risk patients: efficacy and safety results from 2 clinical trials. Poster presented at: 16th European Congress of Clinical Microbiology and Infectious Diseases. April 1-4, 2006. France: Nice, 2006.
55. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Greinix H, Reddy V, Suresh R, Pedicone L, Patino H, Durrant S. Prophylactic treatment of invasive fungal infections with posaconazole or fluconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease [abstract]. Bone Marrow Transplant 2006;37:S163.
56. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole vs fluconazole for prophylaxis of invasive fungal infections in allogeneic hematopoietic stem cell transplantation recipients with graft-versus-host disease: a multicenter trial [abstract m-716]. Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 16-19, 2005. Washington, DC: 2005.